Géraldine Pignot1, Pierre Colin2, Marc Zerbib3, François Audenet4, Michel Soulié5, Sophie Hurel6, Francky Delage7, Jacques Irani8, Aurélien Descazeaud9, Stéphane Droupy10, François Rozet11, Véronique Phé12, Alain Ruffion13, Jean-Alexandre Long14, Sebastien Crouzet15, Alain Houlgatte16, Pierre Bigot17, Laurent Guy18, Pierre-Olivier Faïs19, Morgan Rouprêt4. 1. Academic Department of Urology, Cochin Hospital, Assistance Publique-Hôpitaux de Paris, Faculté de Médecine, Paris Descartes University Paris V, Paris, France. Electronic address: geraldine.pignot@bct.aphp.fr. 2. Academic Department of Urology, CHRU Lille, University Lille Nord de France, Lille, France. 3. Academic Department of Urology, Cochin Hospital, Assistance Publique-Hôpitaux de Paris, Faculté de Médecine, Paris Descartes University Paris V, Paris, France. 4. Academic Department of Urology, La Pitié-Salpetrière Hospital, Assistance Publique-Hôpitaux de Paris, Faculté de Médecine Pierre et Marie Curie, University Paris VI, Paris, France. 5. Academic Department of Urology, CHRU Toulouse, University of Toulouse, Toulouse, France. 6. Academic Department of Urology, CHU Caen, University of Caen, Caen, France. 7. Academic Department of Urology, CHRU Brest, University of Brest, Brest, France. 8. Academic Department of Urology, CHRU Poitiers, University of Poitiers, Poitiers, France. 9. Academic Department of Urology, CHRU Limoges, University of Limoges, Limoges, France. 10. Academic Department of Urology, CHRU Nimes, University of Nimes, Nimes, France. 11. Department of Urology, Institut Mutualiste Montsouris, Paris, France. 12. Academic Department of Urology, Academic Hospital of Foch, Suresnes, France. 13. Academic Department of Urology, CHRU Lyon Sud, Claude Bernard Lyon 1 University, Lyon, France. 14. Academic Department of Urology, CHRU Grenoble, University of Grenoble, Grenoble, France. 15. Academic Department of Urology, Edouard Herriot Hospital, Claude Bernard Lyon 1 University, Lyon, France. 16. Department of Urology, Val de Grace Military Hospital, Paris, France. 17. Academic Department of Urology, CHRU Angers, University of Angers, Angers, France. 18. Academic Department of Urology, CHRU Clermont Ferrand, University of Clermont Ferrand, Clermont Ferrand, France. 19. Academic Department of Urology, CHU Marseille, University of Marseille, Marseille, France.
Abstract
OBJECTIVE: The objective of the study was to evaluate the effect of a history of bladder cancer (BC) or synchronous BC on the prognosis and survival of patients who have undergone radical nephroureterectomy (RNU). METHODS AND MATERIALS: Using a multi-institutional, retrospective database, we identified 662 patients with upper urinary tract urothelial carcinoma (UUT-UC) treated by radical nephroureterectomy, between 1995 and 2010. We analyzed clinicopathologic characteristics and outcomes according to the history of BC or concomitant BC or both, at the time of diagnosis. BC was evaluated as a prognostic factor for bladder recurrence and survival. RESULTS: Overall, 83 (12.5%) patients had previous BC, 62 (9.4%) exhibited concomitant BC, and 75 (11.3%) presented with both previous and current BC. A history of BC was less seen in women and nonsmokers (P<0.0001 and P = 0.013, respectively). The patients with associated BC had more tumors located in the ureter (P<0.0001), as well as more multiple locations in the upper tract (P<0.0001). The tumors without concomitant BC were more likely to be associated with locally advanced stages (P = 0.024). At a median follow-up time of 37.3 months, 31.4% of patients experienced BC recurrence and 2.9% developed contralateral upper tract tumor. Using multivariate analyses, the previous or synchronous BC (P = 0.01) and positive surgical margins (P = 0.03) are independent prognostic factors for BC recurrence. The metastasis-free survival and cancer-specific survival rates did not significantly differ according to the associated BC status. CONCLUSIONS: In patients without previous or concomitant BC, the upper tract tumors are more frequently localized in the renal pelvis and are associated with a more invasive status at the time of diagnosis. Nevertheless, the presence of UUT-UC without previous or synchronous BC did not significantly affect the survival rates after nephroureterectomy.
OBJECTIVE: The objective of the study was to evaluate the effect of a history of bladder cancer (BC) or synchronous BC on the prognosis and survival of patients who have undergone radical nephroureterectomy (RNU). METHODS AND MATERIALS: Using a multi-institutional, retrospective database, we identified 662 patients with upper urinary tract urothelial carcinoma (UUT-UC) treated by radical nephroureterectomy, between 1995 and 2010. We analyzed clinicopathologic characteristics and outcomes according to the history of BC or concomitant BC or both, at the time of diagnosis. BC was evaluated as a prognostic factor for bladder recurrence and survival. RESULTS: Overall, 83 (12.5%) patients had previous BC, 62 (9.4%) exhibited concomitant BC, and 75 (11.3%) presented with both previous and current BC. A history of BC was less seen in women and nonsmokers (P<0.0001 and P = 0.013, respectively). The patients with associated BC had more tumors located in the ureter (P<0.0001), as well as more multiple locations in the upper tract (P<0.0001). The tumors without concomitant BC were more likely to be associated with locally advanced stages (P = 0.024). At a median follow-up time of 37.3 months, 31.4% of patients experienced BC recurrence and 2.9% developed contralateral upper tract tumor. Using multivariate analyses, the previous or synchronous BC (P = 0.01) and positive surgical margins (P = 0.03) are independent prognostic factors for BC recurrence. The metastasis-free survival and cancer-specific survival rates did not significantly differ according to the associated BC status. CONCLUSIONS: In patients without previous or concomitant BC, the upper tract tumors are more frequently localized in the renal pelvis and are associated with a more invasive status at the time of diagnosis. Nevertheless, the presence of UUT-UC without previous or synchronous BC did not significantly affect the survival rates after nephroureterectomy.
Authors: Aurélie Mbeutcha; Morgan Rouprêt; Ashish M Kamat; Pierre I Karakiewicz; Nathan Lawrentschuk; Giacomo Novara; Jay D Raman; Christian Seitz; Evanguelos Xylinas; Shahrokh F Shariat Journal: World J Urol Date: 2016-04-21 Impact factor: 4.226
Authors: Yang Hyun Cho; Young Ho Seo; Seung Jun Chung; Insang Hwang; Ho Song Yu; Sun-Ouck Kim; Seung Il Jung; Taek Won Kang; Dong Deuk Kwon; Kwangsung Park; Jun Eul Hwang; Suk Hee Heo; Geun Soo Kim; Eu Chang Hwang Journal: Korean J Urol Date: 2014-07-11
Authors: Aurélie Mbeutcha; Romain Mathieu; Morgan Rouprêt; Kilian M Gust; Alberto Briganti; Pierre I Karakiewicz; Shahrokh F Shariat Journal: Transl Androl Urol Date: 2016-10